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Signalling between polypeptide growth factors and their specific
receptors is an integral part of the molecular pathways that regu-
late the normal and abnormal growth of solid organs (Cross and
Dexter, 1991). The epidermal growth factor receptor (EGFR) is a
170 kDa transmembrane receptor that plays an important role in
the differentiation and proliferation of epithelial cells (Thompson
and Gill, 1985). Binding of the receptor by any of its ligands (e.g.
the epidermal growth factor [EGF], transforming growth factor-
alpha [TGF-a] or amphiregulin [AR]) results in its activation and
the initiation of a cascade of reactions that ultimately result in
DNA replication and cell division (Gullick, 1998). The EGFR has
previously been implicated in the malignant transformation of
epithelial cells, and high levels of EGFR mRNA and protein have
been found in several solid organ malignancies (Ozanne et al,
1986; Sainsbury et al, 1987; Derynck et al, 1993; Barlett et al,
1996). Amplification and rearrangement of the EGFR gene has
also been associated with over-expression of the receptor protein
in several solid tumours (Xu et al, 1984; Hunts et al, 1985; RO et
al, 1988; Wong et al, 1990).
Earlier reports on EGFR expression in prostatic tumours are
conflicting. Whilst the expression of EGFR mRNA is increased in
these neoplasms (Davies et al, 1988; Morris and Dodd, 1990;
Tukeri et al, 1994; Glynne-Jones et al, 1996), some studies have
shown a gradual decrease in the expression of the receptor protein
with increasing malignant transformation of the epithelial cells
(Maddy et al, 1989; Mellon et al, 1992; Tukeri et al, 1994).
However, other studies reported similar levels of EGFR protein
expression in benign prostatic hyperplasia (BPH) and prostate
cancer (CaP) (Cohen et al, 1994; Glynne-Jones et al, 1996). We
postulated that these contradictory findings were due to the
expression of a mutated EGFR by prostatic tumours.
Several mutations of EGFR have been found in tumours
(Ekstrand et al, 1992; Moscatello et al, 1995; Panneerselvam et al,
1995). The most common of these variant receptors is the
EGFRvIII which has been detected in several cancers (Moscatello
et al, 1995). EGFRvIII results from the deletion of exons 2–7,
which leads to an 801-bp in-frame deletion of the external domain
of the normal receptor (Wong et al, 1990). This rearrangement
removes most of the first two extracellular sub-domains of EGFR,
but preserves the reading frame of the receptor message. As such,
this aberrant EGFR does not bind any known EGFR ligand, but is
a constitutively active tyrosine kinase which initiates mitosis inde-
pendent of ligand-binding. The EGFRvIII has been detected in
tumour cells only and is thought to play a significant role in the
pathogenesis and aggressiveness of cancers (Kristt and Yarden,
1996; Moscatello et al, 1996; Nagane et al, 1996).
There are no previous reports of EGFRvIII detection in prostatic
tumours. Using an antibody that has previously been shown to be
highly specific for this variant receptor (Humphrey et al, 1990;
Wikstrand et al, 1995), as opposed to the native EGFR (WT-EGFR),
we investigated EGFRvIII expression in both benign and malignant
prostatic neoplasms. We have also compared its expression with that
of WT-EGFR in these tissues, and our results support our hypothesis
that the reported reduction of WT-EGFR in prostatic malignancy is
due to the expression of an altered form of the receptor. In addition,
we evaluated the clinical significance of EGFRvIII expression in
CaP and found that the over-expression of this aberrant EGFR is
predictive of an aggressive phenotype of the disease.
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MATERIALS AND METHODS
Clinical materials
Fresh-frozen material
Fresh-frozen tissue for reverse transcription polymerase chain
reaction (RT-PCR) and Western blotting tests were obtained
during transurethral resection of BPH and CaP glands. The chips
were flash frozen to –170°C in liquid nitrogen immediately after
evacuation from the bladder. Routine haematoxylin and eosin
staining was done to confirm histological diagnosis. Chips were
then chosen for subsequent analysis if shown to be either wholly
infiltrated by malignant cells with little intervening stroma (CaP)
or consisting largely of benign hyperplastic glands (BPH).
Archival material
Sections prepared from archival surgical specimens obtained in
1993 from 38 patients with CaP (31 newly diagnosed and seven
hormone-resistant cases) and 19 age-matched patients with BPH,
were supplied by the Pathology Department of Leicester General
Hospital. Paraffin sections from 12 archival metastatic deposits
(six bone and six lymph node) supplied by the Department of
Surgery, Western General Hospital, Edinburgh were also available
for screening. Histological evaluation was performed by routine
haematoxylin and eosin staining of representative sections from
test tissues. The primary CaP specimens were graded using the
Gleason score (Gleason et al, 1974), and classified as benign, well
differentiated (Gleason score 2–4), moderately differentiated
(Gleason score 5–7) or poorly differentiated (Gleason score 8–10).
High-grade prostatic intra-epithelial neoplasia (HG PIN) was seen
in sections from 14 CaP glands.
Clinical data
Data were available for retrieval in all 38 CaP patients, and was
complete in 34 (90%). All data were included for analyses. The
minimum time interval between tissue retrieval and data review
was 36 months. Clinical parameters recorded in addition to age
and histological grade were: (1) serum PSA, (2) hormone status,
(3) presence of metastasis at diagnosis, (4) time to disease progres-
sion following hormonal therapy (a rise in PSA level by greater
than twice the nadir level, or the appearance of new metastases),
(5) survival status, (6) follow-up period or length of survival. The
minimum follow-up period was 36 months and the maximum was
52 months, with a median of 37 months (mean 39.2 months).
Thirteen patients died before the review, and all but 1 death was
from CaP-related causes (as recorded in the death certificates).
RT-PCR
RNA was isolated from fresh-frozen BPH and CaP tissue with
RNAzol B (Tel-Test, Inc., Friendswood, TX, USA) according to
the supplied protocol. Reverse transcription (RT) reactions were
done using 4 mg total RNA and Superscript II Reverse
Transcriptase from Gibco-BRL according to the manufacturer’s
protocol.  Taq Polymerase was from Boehringer Mannheim
(Indianapolis, IN, USA), dNTPs were from Pharmacia Biotech
(Piscataway, NJ, USA), and the primers were synthesized in the
Nucleic Acid Core Facility in the Kimmel Cancer Institute (KCI).
The following primers were used (nucleotides corresponding to
the published WT-EGF receptor cDNA (Ulrich et al, 1984)): 5¢
primers: (1) nt142–159: 5¢ CAg TAT TgA TCg ggA gAg 3¢; (2)
nt180–197: 5¢ AgC AgC gAT gCg ACC CTC 3¢; (3) nt250–266:
5¢ AgT Cgg gCT CTg gAg gA 3¢; 3¢ primers: (4) nt1285–1268:
5¢ CAC TgA Tgg Agg TgC AgT 3¢; and (5) nt1140–1123: 5¢ CAT
CTC ATA gCT gTC ggC 3¢. Primer 4 was used in the RT reaction,
the first PCR reaction used primers 1 and 4, the second PCR reac-
tion used primers 2 and 4, and the third reaction used primers 3
and 5. PCR conditions were as previously described (Wong et al,
1992), except that the annealing temperature used was 53°C. PCR
products were separated on 1.5% agarose TAE gels at 80 V for
1–1.5 h. PCR products were purified for secondary PCR reactions
using the QiaQuick PCR Purification Kit, and for sequencing
using the Gel Extraction Kit, both from Qiagen (Santa Clarita, CA,
USA). PCR products were sequenced using PRISM Ready
Reaction DyeDeoxy Terminator Cycle Sequencing on an Applied
Biosystems Model 377 at the KCI Nucleic Acid Facility.
Antibodies
The antibodies used in this study were: (1) a commercially avail-
able mouse monoclonal anti-EGFR (clone 31G7, Zymed, San
Francisco, CA, USA) which reacts with the peptide backbone of
EGFR and recognizes the WT-EGFR only (Sainsbury et al, 1987);
and (2) a rabbit polyclonal antibody to EGFRvIII produced by
DKM and AJW. This antibody was raised against pepEGFRvIII
(LEEKKGNYVVTDHC) and affinity-purified as previously
described (Humphrey et al, 1990).
Western blotting
Lysates were prepared by homogenizing fresh-frozen tissue
samples of BPH and CaP shown by immunohistochemistry (see
below) to express both forms of EGFR in buffer. Western blot
analysis was carried out as previously described (Laemmli, 1970).
Briefly, 250 mg of protein from BPH and CaP samples along with
aliquots of control lysates (HC2 20d/2c tumour; EGFRvIII positive
control, A431 tumour; WT-EGFR positive control, Jurkat human T-
cell lymphoma; WT-EGFR and EGFRvIII negative control), were
separated on 6% sodium dodecyl sulphate (SDS)-polyacrylamide
gels and transferred onto nitro-cellulose membranes (Amersham,
Bucks, UK). The membranes were incubated with either polyclonal
Table 1 Expression of WT-EGFR in prostatic tissues
Histology Intensity of immunoreaction
(Total no.)
Strong (%) Moderate (%) Weak (%) Absent (%)
Normal/atrophic (19) 17/19 (89) 2/19 (11) 0/19 (0) 0/19 (0)
BPH (19) 13/19 (68) 6/19 (32) 0/19 (0) 0/19 (0)
HG PIN (14) 0/14 (0) 6/14 (43) 8/14 (57) 0/14 (0)
CaP (Cum) (38) 3/38 (8) 4/38 (11) 26/38 (68) 5/38 (13)
G1 (11) 2/11 (18) 2/11 (18) 5/11 (46) 2/11 (18)
G2 (10) 0/10 (0) 1/10 (10) 8/10 (80) 1/10 (10)
G3 (17) 1/17 (6) 1/17 (6) 13/17 (76) 2/17 (12)
Metastases (12) 0/12 (0) 1/12 (8) 1/12 (8) 10/12 (83)
Bone (6) 0/6 (0) 1/6 (17) 0/6 (0) 5/6 (83)
Lymph (6) 0/6 (0) 0/6 (0) 1/6 (17) 6/6 (100)
BPH, benign prostatic hyperplasia; HG PIN, high-grade prostatic intra-
epithelial neoplasia; CaP, carcinoma of the prostate; Cum, cumulative scores.
Detailed distribution of WT-EGFR scores in normal/atrophic, benign
hyperplastic, partially transformed and primary and metastatic malignant
prostatic tissues. Despite the progressive decrease in WT-EGFR expression
with increasing de-differentiation of the glandular cells, WT-EGFR scores
within each tissue histotype was variable.anti-EGFRvIII rabbit antibody, or anti-EGFR mouse monoclonal
antibody. Secondary biotinylated antibodies (Dako, Cambs, UK)
were applied to the membranes which were then developed
according to Amersham’s enhanced chemiluminescence (ECL)
protocol.
Immunohistochemistry
Anti-WT-EGFR and anti-EGFRvIII staining was detected by
streptavidin–biotin amplified immunoperoxidase reactivity. Serial
sections from primary and metastatic prostatic tissues were stained
within 3 weeks of preparation to exclude antigen degradation as
previously described (Olapade-Olaopa et al, 1998). Briefly, after
preparation and exposure of the antigenic epitopes (microwave
and pronase treatment for EGFRvIII and WT-EGFR respectively),
the sections were incubated with the relevant primary (anti-
EGFRvIII or anti-EGFR) and secondary antibodies using the Dako
detection kit. Positive and negative controls were included in all
staining runs. The positive controls were: (1) normal skin for WT-
EGFR; (2) HC2 20d/2c mouse tumour (EGFRvIII). Negative
controls were: (1) monoclonal anti-mouse IgG (WT-EGFR); (2)
normal rabbit serum (EGFRvIII); and (3) normal goat serum.
Antibody cross-reactivity was excluded by staining WT-EGFR
and EGFRvIII positive CaP sections pre-incubated with recombi-
nant EGF (blocking 31G7 binding but not EGFRvIII) with both
antibodies, and by incubating sections of HC2 20d/2c mouse
tumour with anti-WT-EGFR. These sections were negative for
WT-EGFR but positive for EGFRvIII.
Evaluation of immunochemistry
Immuno-reactivity of homogeneous histological areas within the
sections was assessed independently, and without prior knowledge
of histological grading by an experienced pathologist and scored
using a modification of the H-scoring system (Newby et al, 1997).
Briefly, the intensity of the reaction (0–3+) in homogeneous histo-
logical areas of the sections was weighted by the percentage of
cells staining at each intensity. Thus each antibody staining had a
range from 0 (no staining) to 300 (100% 3+ staining). The final
scores were classified as: 0 = negative, 1–33% = low expression,
34–66% = moderate expression, > 66% = high expression.
Statistical methods
The results were reported as proportions and mean scores (± s.d.).
Statistical comparison of mean WT-EGFR and EGFRvIII scores in
individual histological groups was done using the paired and
unpaired two-sample (adjusting for unequal standard deviations) t-
tests as appropriate. Spearman’s correlation coefficient was used
to examine the univariate associations between EGFRvIII expres-
sion and the clinical indices. Multivariate analysis of the expres-
sion of EGFRvIII and the prognostic parameters was done using
Cox’s proportional hazards regression. The impact of EGFRvIII
over-expression on survival was studied using the Kaplan–Meier
method. All tests were two-sided where appropriate and were
performed at the two-sided 0.05 level of significance.
RESULTS
Identification of wild-type and variant EGFR mRNA in
prostatic tumours
Transcripts for the two types of EGFR were detected in both BPH
and CaP. However, the WT-EGFR mRNA was more easily amplified
from both specimens than the EGFRvIII mRNA, as EtBr-stained
188 EO Olapade-Olaopa et al
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Table 2 Expression of EGFRvIII in prostatic tissues
Histology Intensity of immunoreaction
(Total no.)
Strong (%) Moderate (%) Weak (%) Absent (%)
Normal/Atrophic (19) 0/19 (0) 0/19 (0) 0/19 (0) 0/19 (0)
BPH (19) 0/19 (0) 2/19 (11) 17/19 (89) 0/19 (0)
HG PIN (14) 4/14 (29) 10/14 (71) 0/14 (0) 0/14 (0)
CaP Cum (38) 26/38 (68) 10/38 (26) 2/38 (5) 0/38 (0)
G1 (11) 4/11 (36) 5/11 (46) 2/11 (18) 0/11 (0)
G2 (10) 7/10 (70) 3/10 (30) 0/10 (0) 0/10 (0)
G3 (17) 15/17 (88) 2/17 (12) 0/17 (0) 0/17 (0)
Metastases (12) 11/12 (92) 1/12 (8) 0/12 (0) 0/12 (0)
Bone (6) 6/6 (100) 0/6 (0) 0/6 (0) 0/6 (0)
Lymph (6) 5/6 (83) 1/6 (17) 0/6 (0) 0/6 (0)
BPH, benign prostatic hyperplasia; HG PIN, high-grade prostatic intra-
epithelial neoplasia; CaP, carcinoma of the prostate; Cum, cumulative
scores. Detailed distribution of EGFRvIII scores in normal/atrophic, benign
hyperplastic, partially transformed and primary and metastatic malignant
prostatic tissues. As seen in anti-WT-EGFR immunostaining there was
variability in the level of EGFRvIII expression within individual histological
grades.
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Figure 1 RT-PCR detection of WT-EGFR and EGFRvIII mRNA transcripts
in BPH and CaP. The upper arrow indicates the expected 890 bp WT-EGFR
band and the lower arrow the 89 bp EGFRvIII band generated by nested
PCR using primers 3 and 5 as described in the Methods.
Immunohistochemical staining of representative sections from these
specimens showed high WT-EGFR and low EGFRvIII levels in the BPH
tissue, whilst the CaP sample stained strongly for EGFRvIII and weakly for
WT-EGFREGFRvIII in prostate cancer 189
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WT-WGFR bands could be seen after nested PCR, but a tertiary PCR
reaction was necessary to visualize the EGFRvIII band (Figure 1 and
data not shown).
Detection of WT-EGFR and EGFRvIII proteins and
confirmation of antibody specificity
Anti-EGFRvIII immunoblotting detected a 148-kDa band in BPH
and CaP lysates which corresponds to the variant EGFR (Figure
2A). A weak EGFRvIII signal was also seen in the 90 kDa region
in the CaP lysate. On the other hand, Western blot analysis of these
samples using the anti-WT-EGFR detected a 170 kDa protein
only, corresponding to the native EGFR in both tumour lysates
(Figure 2B). As such, as well as detecting the presence of both
WT-EGFR and EGFRvIII protein, these results further confirmed
the specificity of the antibodies for their respective antigens.
Localization of WT-EGFR and EGFRvIII immunostaining
in prostatic tissues
Primary prostatic tumours (BPH and CaP) are heterogeneous
diseases, and glands of different histotypes may be adjacent to
each other within tumour sections. We found that WT-EGFR and
EGFRvIII pattern of staining was dependent on the histology of
the individual glands within our sections as similar immuno-
reactions were seen in normal/atrophic and BPH glands in both
BPH and CaP sections. We also determined that WT-EGFR
expression was mainly membranous and that staining was
strongest in the basal cells of the glands (Figure 3 A–D). In
contrast, although some membranous EGFRvIII staining was seen,
the variant antigen was expressed mainly in the cytoplasm, and
this for the most part appeared as a distinct peri-nuclear deposit on
the luminal surface of the cells (Figure 4 B–D).
WT-EGFR protein expression is decreased in prostatic
neoplasms
The highest expression of WT-EGFR protein was seen in
normal/atrophic glands, and the mean expression of this normal
receptor decreased as the epithelial cells de-differentiated (Table
1A and Figure 3A–G). Statistical comparison of the mean scores
in the various histological groups revealed that the progressive
decrease in WT-EGFR was highly significant, i.e. normal/atrophic
vs BPH, and BPH vs HG PIN and CaP glands (P ≤ 0.0001). WT-
EGFR expression was also significantly lower in metastatic
deposits than in CaP glands (P = 0.015). However, the levels of
expression of the normal receptor in HG PIN and CaP glands were
statistically similar (P = 0.41), as were the mean scores in early
and advanced CaP tumours (G1 vs G2/3) (P = 0.12).
EGFRvIII protein is expressed by neoplastic prostatic
cells only
In contrast to the normal receptor, EGFRvIII was expressed by
abnormal prostatic epithelial cells only and not by normal glands.
Furthermore, the mean EGFRvIII expression increased as the
tumours became more malignant with poorly differentiated
tumours and metastases staining the strongest (Table 1B and
Figure 4A–G). Statistical comparison of the scores revealed
significant differences between EGFRvIII expression in benign
and partially or fully transformed glands: BPH vs HG PIN or CaP
(P = < 0.0001), and also between CaP and metastases (P = 0.004).
However, in contrast to WT-EGFR, EGFRvIII expression in the
higher grade tumours (G2 and G3) was significantly higher than in
well-differentiated (G1) tumours (P = 0.006).
Hormone-resistant CaP glands have higher levels of
EGFRvIII protein expression
We compared EGFRvIII and WT-EGFR expression in newly diag-
nosed (hormone-naive) and hormone-resistant glands. We found
that whilst EGFRvIII expression was significantly higher in
hormone resistant CaP than in untreated glands (P = 0.012), mean
WT-EGFR expression was similar in the two groups (P = 0.86).
1
7
0
 
k
D
a
CaP
BPH
Jurkat lymphoma
A431
HC2d
CaP
BPH
Jurkat lymphoma
A431
HC2d
B
L
O
T
:
a
E
G
F
R
 
(
3
1
G
7
)
B
L
O
T
:
 
a
E
G
F
R
v
I
I
I
1
7
0
 
k
D
a
1
4
8
 
k
D
a
1
0
0
 
k
D
a
(a)
(b)
Figure 2 Expression of WT-EGFR and EGFRvIII in BPH and CaP analysed
by Western blotting. Aliquots of lysates containing 250 mg of BPH and CaP,
25 mg of HC2 20d/2c tumour (EGFRvIII positive control), 50 mg of A431
tumour (WT-EGFR-positive control), and 50 mg of Jurkat human T-cell
lymphoma (EGFR-negative control) were added to the wells. The lysates
were run on 7.5% PAGE at 200 mV, and then immunoblotted with antibodies
to either the wild-type or variant EGF receptor. A single band of proteins was
recognized in the 170 kDa region in BPH and CaP by anti-WT-EGFR clone
31G7, whilst bands of protein were detected by the anti-EGFRvIII antibody in
BPH and CaP lysates in the 140 kDa region. A 90 kDa band was also seen in
the HC2 20d/2c and CaP lanes of the EGFRvIII blot confirming the
expression of multiple isoforms of the mutated protein by tissues which
overexpress the EGFRvIII as previously reported (Ekstrand et al, 1992;
Moscatello et al, 1995, 1996). Specificity of the antibodies used is confirmed
by the strong anti-WT-EGFR signal seen at 170 kDa region in A431 lane and
anti-EGFRvIII signal seen in the HC2 20d/2c lane in the absence of cross-
reactions (signals) in these respective lanes in the immunoblots for each
antigen. There were no signals in the negative control lanes in either blot190 EO Olapade-Olaopa et al
British Journal of Cancer (2000) 82(1), 186–194 © 2000 Cancer Research Campaign
A
C D
E
F
G
Figure 3 WT-EGFR immunostaining in prostatic tumours (´ 250). Sections
were counterstained with haematoxylin. (A) Normal/atrophic glands showing
high WT-EGFR expression. (B) BPH glands showing moderate expression of
WT-EGFR. (C) HG PIN glands showing minimal WT-EGFR staining of
transformed cells whilst basal cells of adjacent benign gland showed strong
immunoreactivity. (D) Weak WT-EGFR expression in CaP glands.
(A–D) Membranous WT-EGFR immunoreaction was strongest in basal cells
and appeared as an outer rim surrounding the glands. (E) Lymph node
metastasis showing no WT-EGFR staining in cells of prostatic or lymphoid
origin. (F) Metastatic prostatic deposit in bone also showing no WT-EGFR
expression in either the invading or native cells of the tissue. (G) WT-EGFR
negative control (BPH section ´ 100)EGFRvIII in prostate cancer 191
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Figure 4 EGFRvIII immunostaining in serial sections from prostatic tumours
counterstained with haematoxylin (´250). (A) EGFRvIII was not expressed in
normal/atrophic glands. (B) Weak EGFRvIII immuno-reaction in BPH glands.
(C) HG PIN gland showing strong EGFRvIII staining in fully transformed cells
whilst histologically benign cells within the gland and the adjacent BPH gland
stained weakly. (D) Strong expression of EGFRvIII in CaP glands. 
(A–D) Cytoplamic EGFRvIII staining was seen mainly as a perinuclear
deposit on the luminal side of the tumour cells and gave an impression
of an inner rim within fully formed glands. (E) Metastatic prostatic cells in a
lymph node showing strong EGFRvIII staining in the midst of negative
lymphoid cells. (F) CaP deposit in bone showing high EGFRvIII expression
in the metastatic cells whilst surrounding osteocytes are negative
(G) EGFRvIII-negative control (CaP section ´ 100)Also, co-expression of WT-EGFR and EGFRvIII was seen in 7/7
(100%, confidence interval (CI) 59–100%) of sections from
hormone resistant glands as compared to 26/31 (84%, CI 66–95%)
of sections from untreated CaP, but this difference was not statisti-
cally significant (c2, P = 0.77).
EGFRvIII protein expression is indicative of an
aggressive prostate cancer phenotype
We assessed the effect of EGFRvIII expression on the clinical
course of CaP by correlating EGFRvIII scores with accepted prog-
nostic parameters for survival of patients with CaP (age, serum
prostate-specific antigen (PSA), histological grade, and patholog-
ical and clinical stage) (Sakr and Grigon, 1997). The duration of
response to hormonal manipulation (time to disease progression)
is also a useful indicator of the aggressiveness of CaP. EGFRvIII
expression was significantly related to serum PSA (P = 0.005)
(Figure 5), and the time to disease progression (P = 0.05) only. At
the time of data review, 12 patients had died from CaP-related
causes but the level of EGFRvIII expression did not have a signif-
icant influence on survival during the follow-up period (P = 0.83)
(Figure 6).
Univariate analysis of the relationship between the prognostic
factors and the survival of our patients revealed that only the time to
disease progression following hormone therapy (P = 0.007), and the
presence of metastasis at diagnosis (i.e. advanced disease at presen-
tation) (P = 0.04) had a significant impact on survival. Although
EGFRvIII activity was not significant as an individual prognostic
factor for CaP, its association with the time to disease progression
indicates its over-expression may be predictive of a poor response to
hormonal manipulation. Multivariate analysis using Cox’s propor-
tional hazards showed that only an advanced clinical stage had a
significant influence on survival at 3 years (P = 0.01).
DISCUSSION
Since we first detected the presence of EGFR in BPH (Maddy et
al, 1987), there have been conflicting reports on the levels of the
receptor protein found in prostatic tumours (Maddy et al, 1989;
Maygarden et al, 1992; Mellon et al, 1992; Cohen et al, 1994;
Tukeri et al, 1994; Glynne-Jones et al, 1996). In this current study,
using two independent investigative techniques, we have shown
for the first time the presence of a variant EGF receptor in prostatic
tumours. Furthermore, although EGFRvIII has been detected in
other cancers, to our knowledge this is the first study to evaluate
its association with WT-EGFR in human neoplasms. Despite the
small numbers of specimens incorporated in our project, the
consistency of the inverse relationship between the level of
immuno-reactivity of these two antigens through all stages of
prostatic differentiation scrutinized, supports our hypothesis
that the progressive decrease in EGFR expression in prostatic
neoplasms is due to the differential expression of an altered
receptor by abnormal epithelial cells of this gland. As there is
192 EO Olapade-Olaopa et al
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Figure 5 A scatter graph comparing EGFRvIII scores with serum PSA
levels in individual CaP patients. This showed a significant association
between EGFRvIII expression and serum PSA level at the time of tissue
retrieval (P = 0.005)
Figure 6 Kaplan–Meier overall survival estimates showing minimal effect of
EGFRvIII over-expression on the survival of CaP patients in this study
Figure 7 Graphical representation of WT-EGFR and EGFRvIII mean
scores (± s.d.) in the different histological grades of prostatic tissues
demonstrating an inverse relationship between the levels of expression of
the two types of EGF receptors. The different between WT-EGFR and
EGFRvIII mean scores (± s.d.) was statistically significant in each tissue
histiotype (P = < 0.0001)EGFRvIII in prostate cancer 193
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increasing evidence from clinical and basic science research that
PIN is a precursor of invasive prostatic disease (Haggman et al,
1997), our findings are further validated by our demonstration that
WT-EGFR and EGFRvIII levels in HG PIN were intermediate
between those recorded in BPH and CaP glands.
Interestingly whilst both WT-EGFR and EGFRvIII mRNA were
detected in both BPH and CaP, the expression of the variant
receptor protein increased with de-differentiation of prostatic
epithelial cells with a concomitant decrease in WT-EGFR expres-
sion (Figure 7). This suggests that as prostatic tumours advance
they increasingly express this constitutively active variant protein
in preference to the normal receptor. Further support is offered by
our finding of a higher expression of EGFRvIII in sections from
hormone resistant CaP sections and by previous reports of the
detection constitutive EGFR activity in androgen-independent
prostate cancer cell lines (Sherwood et al, 1998). We have recently
reported that malignant transformation of prostatic epithelium is
associated with a loss of androgen receptor expression in stromal
cells, and postulated that this may result in the loss of stromal
derived epithelial mitogens (ligands) (Olapade-Olaopa et al,
1999). In this event, the reliance of neoplastic prostatic glands on
ligand-independent pathways (such as the expression of a constitu-
tively active receptor) may be a response to the cessation of prolif-
erative signals from the stromal compartment.
Although the specificity of our antibodies was confirmed by
Western blotting and the inclusion of positive and negative controls
in the immuno-staining tests, our immunohistochemical data also
showed that the staining patterns of anti-WT-EGFR and anti-
EGFRvIII in prostatic tissues differed. Immunohistochemistry
affords direct visualization of the cellular component where the
antigen–antibody reaction occurs, and we found that whilst WT-
EGFR immuno-reactions were on the cell-membrane, EGFRvIII
expression was mainly cytoplasmic/perinuclear. The presence of a
perinuclear deposit in EGFRvIII-positive prostate cells is similar to
earlier observations in glial tumours (Nishakawa et al, 1994;
Moscatello et al, 1996), and may be due to the immuno-localization
of the internalized variant receptor (following ligand-independent
dimerization). The significance of this difference in the cellular
distribution of the two types of EGFR is at present unclear.
In common with other studies, this variant EGFR was expressed
by prostatic tumour cells only with no evidence for its expression
in normal cells. The demonstrable specificity and sensitivity of
high EGFRvIII expression by (partially or fully) malignant cells
only in HG PIN, CaP and metastases (including those cells that did
not stain for PSA), indicates the potential usefulness of the
EGFRvIII as a marker when screening tissues for malignant
prostatic cells especially when PSA staining is weak or absent
(Bostwick et al, 1998).
In previous studies of EGFRvIII expression in glioblastomas,
high levels were found preferentially in advanced tumours (grades
III and IV) (Wong et al, 1987). Other studies have also shown that
EGFRvIII increases the tumorigenicity of malignant epithelial
cells by increasing mitosis and reducing apoptosis (Nagane et al,
1996), and also by increasing their metastatic potential
(Nishakawa et al, 1994; Moscatello et al, 1996). The increasing
levels of EGFRvIII detected as prostatic neoplasms progressed
from intraepithelial changes to metastatic disease, and the finding
that EGFRvIII expression is predictive of a poor response to
hormone therapy, suggests that over-expression of this antigen
may contribute to both the malignant transformation of prostatic
cells and the subsequent progression to hormone insensitivity. In
addition, co-expression of WT-EGFR and EGFRvIII was found in
all hormone resistant glands. EGFRvIII is known to increase the
mitotic activity of WT-EGFR (Nishakawa et al, 1994), and it is
possible that the possession of two different mitotic pathways,
which act in synergy, is desirable for hormone-independent prolif-
eration by prostatic cells in vivo.
Growth factors and receptors are recognized as potentially
effective targets of anticancer therapies (Greig et al, 1988;
Modjtahedi et al, 1996), but the down-regulation of the EGFR
protein in prostatic malignancies has limited trials of these treat-
ments in these tumours. However, there are recent reports of
promising results with monoclonal antibodies that inhibit constu-
tive EGFR phosphorylation (Fong et al, 1992), as well as drugs
directed at the receptor signalling pathways (Putz et al, 1999) in
CaP cell lines. We have recently reported that the immunization
of immunocompetent laboratory animals with anti-EGFRvIII
vaccines stimulated the regression of established tumours
(Moscatello et al, 1997). Furthermore, expression of EGFRvIII
has been shown to markedly increase the sensitivity of epithelial
cells to anti-EGF-receptor-specific toxins (Schmidt et al, 1998). In
the light of these reports, the specificity of high EGFRvIII expres-
sion for malignant prostatic cells suggests that this variant receptor
may be a suitable target for novel treatment options in CaP
including gene therapy.
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